Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Y-mAbs Therapeutics Inc YMAB

Healthcare Biotechnology
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product... see more

Recent & Breaking News (NDAQ:YMAB)

Y-mAbs Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Developments

GlobeNewswire February 24, 2022

Y-mAbs to Announce 2021 Financial and Operating Results on February 24, 2022

GlobeNewswire February 17, 2022

Y-mAbs Announces Completion of Pre-BLA Meeting with FDA for Omburtamab

GlobeNewswire February 11, 2022

Y-mAbs Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 5, 2022

UPDATE - Y-mAbs Announces Pipeline Update

GlobeNewswire December 15, 2021

Y-mAbs Announces Pipeline Update

GlobeNewswire December 15, 2021

Y-mAbs Hosting Virtual Research and Development Day

GlobeNewswire December 6, 2021

Y-mAbs Announces Third Quarter Financial Results and Recent Corporate Developments

GlobeNewswire November 4, 2021

Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma CNS/LM Metastasis

GlobeNewswire November 4, 2021

Y-mAbs to Announce Third 2021 Financial and Operating Results on November 4, 2021

GlobeNewswire October 28, 2021

Y-mAbs' 177Lu-omburtamab-DTPA for the Treatment of Patients with Medulloblastoma Granted Rare Pediatric Disease Designation by FDA

GlobeNewswire October 7, 2021

Y-mAbs Announces Data to be Presented at SIOP 2021

GlobeNewswire September 16, 2021

Y-mAbs Announces Priority Review of BLA for DANYELZA® (naxitamab-gqgk) in China

GlobeNewswire September 13, 2021

Y-mAbs to Host Key Opinion Leader Webinar on DANYELZA® (naxitamab-gqgk) Frontline and HITS Data in High-Risk Neuroblastoma

GlobeNewswire September 10, 2021

Y-mAbs Announces Second Quarter Financial Results and Recent Corporate Developments

GlobeNewswire August 5, 2021

Y-mAbs to Announce Second Quarter 2021 Financial and Operating Results on August 5, 2021

GlobeNewswire July 29, 2021

Y-mAbs Announces NMPA Submission of BLA for DANYELZA® (naxitamab-gqgk) in China

GlobeNewswire July 6, 2021

Y-mAbs' 177Lu-omburtamab-DTPA for the Treatment of Patients with Medulloblastoma Receives Positive Opinion on Orphan Medicinal Product Designation by EMA

GlobeNewswire June 25, 2021

Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma

GlobeNewswire June 23, 2021

Y-mAbs Announces Frontline Data for DANYELZA® (naxitamab-gqgk) in High-Risk Neuroblastoma

GlobeNewswire June 4, 2021